Abbott Laboratories (ABT) Total Liabilities (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Total Liabilities data on file, last reported at $110.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 35.58% year-over-year to $110.4 billion; the trailing twelve-month figure through Mar 2026 stood at $110.4 billion (up 35.58% YoY), and the FY2025 full-year result was $86.7 billion, up 6.51% from the prior year.
• Total Liabilities advanced to $110.4 billion in Q1 2026, from $86.7 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $110.4 billion in Q1 2026 to a low of $8.0 billion in Q4 2022.
• A 5-year average of $74.7 billion and a median of $74.0 billion in 2022 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities surged 816.89% in 2023 and dropped 1.8% in 2024, its largest moves.
• Tracing ABT's Total Liabilities over 5 years: stood at $8.0 billion in 2022, then surged by 816.89% to $73.2 billion in 2023, then increased by 11.2% to $81.4 billion in 2024, then advanced by 6.51% to $86.7 billion in 2025, then grew by 27.35% to $110.4 billion in 2026.
• Business Quant data shows ABT's Total Liabilities at $110.4 billion in Q1 2026, $86.7 billion in Q4 2025, and $84.2 billion in Q3 2025.